Journal of Clinical Endocrinology and Metabolism |

Popular Keywords

Antifungal Drug Resistance

Biodiversity

Ecology

Environmental and Ecological Interactions of Fungi

Food

Forest

Gaining Ground Gradually Over 25 Years: GLP-1 Receptor Development as a Successful Weight Loss Target.

Correspondence to Author: David A. D’Alessio,

Lipids, Nutrition, and Cardiovascular Prevention Clinic of the Montreal Clinical Research Institute, 110 avenue des Pins Ouest, Montreal, Québec, Canada, H2W 1R7.

ABSTRACT:
Glucagon-like peptide 1 (GLP-1) receptor agonists are effective and safe weight-loss medications, according to recent data from clinical trials. GLP-1 receptor agonists were initially created as medications to lower blood sugar levels in individuals with type 2 diabetes, but advancements in research over the past three decades have shown that they also function by acting on the central nervous system to decrease appetite. The main points of GLP-1 biology and the clinical research demonstrating the GLP-1 receptor signaling system’s potential as a weight loss treatment target are outlined in this minireview.

Citation:

David A. D’Alessio. Gaining Ground Gradually Over 25 Years: GLP-1 Receptor Development as a Successful Weight Loss Target. Journal of Clinical Endocrinology and Metabolism 2024.